Victory Capital Management Inc. Purchases 237,497 Shares of Immunome, Inc. (NASDAQ:IMNM)

Victory Capital Management Inc. lifted its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 48.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 730,785 shares of the company's stock after purchasing an additional 237,497 shares during the quarter. Victory Capital Management Inc. owned about 1.22% of Immunome worth $10,684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMNM. Price T Rowe Associates Inc. MD lifted its position in Immunome by 113.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company's stock worth $55,425,000 after purchasing an additional 1,194,451 shares during the period. Marshall Wace LLP lifted its holdings in shares of Immunome by 228.5% in the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company's stock valued at $20,731,000 after buying an additional 1,191,774 shares during the period. Redmile Group LLC boosted its stake in Immunome by 26.0% during the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company's stock valued at $120,674,000 after buying an additional 1,010,139 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Immunome during the first quarter worth about $14,660,000. Finally, Vanguard Group Inc. grew its holdings in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company's stock worth $49,847,000 after acquiring an additional 279,712 shares during the period. Institutional investors own 44.58% of the company's stock.

Analyst Upgrades and Downgrades

IMNM has been the subject of several research reports. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an "overweight" rating and a $30.00 target price for the company. Finally, Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $28.83.

Insider Buying and Selling

In related news, CFO Max Rosett sold 14,380 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares of the company's stock, valued at approximately $760,090.76. This represents a 23.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.60% of the company's stock.

Immunome Trading Down 0.6 %

Shares of IMNM opened at $9.33 on Thursday. The company has a 50-day moving average of $12.81 and a two-hundred day moving average of $13.67. Immunome, Inc. has a one year low of $6.93 and a one year high of $30.96.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.